American Cyanamid Company

Schering Corporation

Michael R Ostrander

Yakov Gluzman

George H Miller

Tattanahali L Nagabhushan

Joseph M Backer

Jerome Schwartz

The present invention relates to methods for controlling and/or treating RNA-replicating viral infections which afflict human beings, animals and/or plants. Specifically, the RNA chain terminating agents, 3'-deoxyribouracil, 3'-deoxyriboguanine and 3'-deoxyribocytosine are useful in treating RNA-replicating viral infections.

Method for treating RNA viral infections by using RNA chain terminators

The disclosure relates to a method of inhibiting the infectivity of a virus, the virus being characterized by the presence of a heparin-binding protein, which comprises contacting the cellular receptor for the virus or the receptor-binding protein of the virus with an effective amount of a pharmaceutical composition containing the HBNF protein, the MK protein or a combination thereof in a sufficient amount to inhibit the infectivity of the virus. Also, this disclosure concerns a method of preventing or treating a viral infection in a subject, the virus being characterized by the presence of a heparin-binding protein, which comprises administering to the subject an effective amount of a pharmaceutical composition containing HBNF, MK or a combination thereof in a sufficient amount to prevent or treat the viral infection in the subject. Further, the disclosure describes a new composition comprising a combination of the HBNF and MK proteins. Both HBNF and MK possess heparin-binding activity, displace bFGF from high affinity receptors and inhibit growth of endothelial cells.

Method of treating herpes viral infections using HBNF and MK proteins

Treatment of viral infections with combinations of cyclaradine and interferon and compositions and kits used therein are disclosed.

Growing community of inventors

Glen Ridge, NJ, United States of America

Michael R Ostrander